Form 8-K - Current report:
SEC Accession No. 0001193125-24-059397
Filing Date
2024-03-05
Accepted
2024-03-05 17:08:05
Documents
17
Period of Report
2024-03-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d804826d8k.htm   iXBRL 8-K 26195
2 EX-1.1 d804826dex11.htm EX-1.1 165254
3 EX-5.1 d804826dex51.htm EX-5.1 8311
7 GRAPHIC g804826g0305052334832.jpg GRAPHIC 2534
  Complete submission text file 0001193125-24-059397.txt   375941

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20240304.xsd EX-101.SCH 2849
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20240304_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20240304_pre.xml EX-101.PRE 11260
18 EXTRACTED XBRL INSTANCE DOCUMENT d804826d8k_htm.xml XML 3636
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 24722124
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)